Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than what ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...

GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome; CAD: Coronary artery disease; CHF: Congestive heart failure; CRF: Chronic renal ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications ... These medications work by mimicking the effects of GLP-1, a hormone that plays a crucial role in regulating ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

GLP-1 agonist initiators had a significantly higher likelihood of undergoing thyroid ultrasonography at 6 and 12 months, suggesting detection bias was behind the increased cancer diagnosis rate ...

These Glucagon Like Peptide-1 (GLP-1) agonists (meaning they combine ... a quiet collegial personality who thought about her work and family rather than awards, came from Yugoslavia. She completed her ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such ... concluded that the data “does not support a causal ...

For GLP-1 receptors ... largely thanks to Knudsen’s work, with slight changes to allow them to hang out in the blood longer than GLP-1 normally does. GLP-1 briefly slows the rate food moves ...